Duality Biologics

Jiangsu Hengrui Pharmaceuticals, China’s top drug developer by size of pipeline, is set to stage the world’s biggest new share sale by a pharmaceutical company so far in 2025 by raising up to HKD9.89b

As it gears up to submit BNT323 (trastuzumab pamirtecan) to the US Food and Drug Administration for endometrial cancer, BioNTech is also hoping to diversify the supply base for the drug from China, wh

The uncertainty created by potential tariffs and US healthcare strategies has seen some senior pharma figures express concern about the impact on M&A but GSK CEO Emma Walmsley is confident that de

Shanghai Henlius Biotech is trying to play a David versus Goliath game of catch-up with Pfizer, in pursuit of the commercialization of the world’s first PD-L1-targeting antibody-drug conjugate (ADC).